In a reader survey, researchers and core lab staff share how they think cores are doing.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.
Scotland's Arrayjet will provide the Bronx-based NYBC with microarray instrumentation, printing, and expertise under an approximately $250,000 contract.
The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
London Health Sciences Center researchers published a study validating the accuracy of the method as a potential screening test for symptomatic male patients.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.